Oncology 类别的文章 - Peeref

Article Oncology

Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zi-Xian Wang, Chengxu Cui, Jun Yao, Yanqiao Zhang, Mengxia Li, Jifeng Feng, Shujun Yang, Yun Fan, Jianhua Shi, Xizhi Zhang, Lin Shen, Yongqian Shu, Cailian Wang, Tianyang Dai, Teng Mao, Long Chen, Zengqing Guo, Bo Liu, Hongming Pan, Shundong Cang, Yi Jiang, Junye Wang, Min Ye, Zhendong Chen, Da Jiang, Qin Lin, Wei Ren, Junsheng Wang, Lin Wu, Yong Xu, Zhanhui Miao, Meili Sun, Conghua Xie, Ying Liu, Qifeng Wang, Lina Zhao, Qi Li, Canhong Huang, Ke Jiang, Kunyu Yang, Daojun Li, Yunpeng Liu, Zhitu Zhu, Rixin Chen, Liqun Jia, Wei Li, Wangjun Liao, Hong-Xu Liu, Daiyuan Ma, Jie Ma, Yanru Qin, Zhihong Shi, Qichun Wei, Ke Xiao, Yan Zhang, Ying Zhang, Xin Chen, Guanghai Dai, Jianxing He, Junhe Li, Guanghui Li, Yong Liu, Zhihua Liu, Xianglin Yuan, Junping Zhang, Zhichao Fu, Yifu He, Fang Ju, Zheng Liu, Peng Tang, Tiejun Wang, Weibo Wang, Jing Zhang, Xianming Luo, Xiongwen Tang, Rena May, Hui Feng, Sheng Yao, Patricia Keegan, Rui-Hua Xu, Feng Wang

Summary: This study found that toripalimab combined with paclitaxel and cisplatin can significantly improve progression-free survival and overall survival in patients with treatment-naive advanced esophageal squamous cell carcinoma, with manageable safety.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

Cancer statistics for African American/Black People 2022

Angela N. Giaquinto, Kimberly D. Miller, Katherine Y. Tossas, Robert A. Winn, Ahmedin Jemal, Rebecca L. Siegel

Summary: African American/Black individuals bear a disproportionate cancer burden, with high mortality and low survival rates compared to other racial/ethnic groups. Data from the American Cancer Society shows that in 2018, there were significant disparities in cancer incidence, mortality, survival, screening, and risk factors among Black people in the United States. The projected numbers for 2022 indicate a high number of new cancer cases and deaths among Black individuals. Black men have higher incidence and mortality rates for certain cancers, such as myeloma, stomach cancer, and prostate cancer. The disparity in overall cancer mortality between Black and White men is narrowing, but the decline in prostate cancer mortality among Black men has slowed. Black women have a lower incidence rate but higher mortality rates for certain cancers, such as endometrial and breast cancer. Breast cancer has become the leading cause of cancer death among Black women.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Review Oncology

Ferroptosis in cancer and cancer immunotherapy

Lei Zhao, Xiaoxue Zhou, Feng Xie, Lei Zhang, Haiyan Yan, Jun Huang, Chong Zhang, Fangfang Zhou, Jun Chen, Long Zhang

Summary: Ferroptosis, a newly identified type of cell death dependent on lipid peroxidation, plays a vital role in cancer treatment as a potential strategy to overcome drug resistance in traditional therapies.

CANCER COMMUNICATIONS (2022)

添加到收藏夹

Article Oncology

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. G. Casali, J. Y. Blay, N. Abecassis, J. Bajpai, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I Boukovinas, J. V. M. G. Bovee, K. Boye, T. Brodowicz, A. Buonadonna, E. De Alava, A. P. Dei Tos, X. G. Del Muro, A. Dufresne, M. Eriksson, A. Fedenko, V Ferraresi, A. Ferrari, A. M. Frezza, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, R. Haas, A. B. Hassan, N. Hindi, P. Hohenberger, H. Joensuu, R. L. Jones, C. Jungels, P. Jutte, B. Kasper, A. Kawai, K. Kopeckova, D. A. Krakorova, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez-Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, A. B. Miah, O. Mir, M. Montemurro, C. Morosi, E. Palmerini, M. A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, A. A. Safwat, C. Sangalli, M. Sbaraglia, S. Scheipl, P. Schoffski, S. Sleijfer, D. Strauss, S. J. Strauss, K. Sundby Hall, A. Trama, M. Unk, M. A. J. van de Sande, W. T. A. van der Graaf, W. J. van Houdt, T. Frebourg, A. Gronchi, S. Stacchiotti

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Cancer vaccines as promising immuno-therapeutics: platforms and current progress

Jian Liu, Minyang Fu, Manni Wang, Dandan Wan, Yuquan Wei, Xiawei Wei

Summary: Research on tumor immunotherapy has made significant progress, and cancer vaccines have emerged as a promising therapeutic strategy. Cancer vaccines stimulate anti-tumor immunity with tumor antigens, potentially overcoming immune suppression and inducing both humoral and cellular immunity. This review introduces the working mechanism of cancer vaccines, summarizes different development platforms, and highlights their clinical research progress, with a focus on clinical application and therapeutic efficacy.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

J. Haanen, M. Obeid, L. Spain, F. Carbonnel, Y. Wang, C. Robert, A. R. Lyon, W. Wick, M. Kostine, S. Peters, K. Jordan, J. Larkin

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer

Vikrant Kumar, Kalpana Ramnarayanan, Raghav Sundar, Nisha Padmanabhan, Supriya Srivastava, Mayu Koiwa, Tadahito Yasuda, Vivien Koh, Kie Kyon Huang, Su Ting Tay, Shamaine Wei Ting Ho, Angie Lay Keng Tan, Takatsugu Ishimoto, Guowei Kim, Asim Shabbir, Qingfeng Chen, Biyan Zhang, Shengli Xu, Kong-Peng Lam, Huey Yew Jeffrey Lum, Ming Teh, Wei Peng Yong, Jimmy Bok Yan So, Patrick Tan

Summary: This study generated a comprehensive single-cell atlas of gastric cancer, providing molecular insights into the intra- and interpatient lineage states across distinct subtypes. The findings are important for understanding gastric cancer heterogeneity and developing relevant therapeutic strategies.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies

Md Sanower Hossain, Hidayah Karuniawati, Ammar Abdulrahman Jairoun, Zannat Urbi, Der Jiun Ooi, Akbar John, Ya Chee Lim, K. M. Kaderi Kibria, A. K. M. Mohiuddin, Long Chiau Ming, Khang Wen Goh, Muhammad Abdul Hadi

Summary: Colorectal cancer (CRC) is a highly lethal disease with increasing incidence and mortality worldwide. Early detection and treatment are essential for survival, but recurrence and drug resistance pose significant challenges. This comprehensive review addresses the development, risk factors, and management strategies of CRC. In addition, natural products as potential therapeutics are also discussed. Public awareness is crucial for improving CRC management, especially in developing countries where access to diagnosis and treatment resources is limited.

CANCERS (2022)

添加到收藏夹

Article Oncology

Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

Fernanda G. Herrera, Catherine Ronet, Maria Ochoa de Olza, David Barras, Isaac Crespo, Massimo Andreatta, Jesus Corria-Osorio, Aodrenn Spill, Fabrizio Benedetti, Raphael Genolet, Angela Orcurto, Martina Imbimbo, Eleonora Ghisoni, Blanca Navarro Rodrigo, Dominik R. Berthold, Apostolos Sarivalasis, Khalil Zaman, Rafael Duran, Clarisse Dromain, John Prior, Niklaus Schaefer, Jean Bourhis, Georgia Dimopoulou, Zoi Tsourti, Marius Messemaker, Thomas Smith, Sarah E. Warren, Periklis Foukas, Sylvie Rusakiewicz, Mikael J. Pittet, Stefan Zimmermann, Christine Sempoux, Urania Dafni, Alexandre Harari, Lana E. Kandalaft, Santiago J. Carmona, Denarda Dangaj Laniti, Melita Irving, George Coukos

Summary: Developing strategies to inflame tumors is critical for increasing response to immunotherapy. Low-dose radiation reprograms the tumor microenvironment to promote T-cell infiltration and, when combined with immunotherapy, simultaneously mobilizes innate and adaptive immunity, predominantly CD4(+) effector T cells, for tumor control dependent on NKG2D. This combination induces important responses in patients with metastatic immune-cold tumors.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers

Kuo Chen, Pengwei Lu, Narasimha M. Beeraka, Olga A. Sukocheva, SubbaRao Madhunapantula, Junqi Liu, Mikhail Y. Sinelnikov, Vladimir N. Nikolenko, Kirill Bulygin, Liudmila M. Mikhaleva, Igor Reshetov, Yuanting Gu, Jin Zhang, Yu Cao, Siva G. Somasundaram, Cecil E. Kirkland, Ruitai Fan, Gjumrakch Aliev

Summary: This article discusses the role of epigenetic regulation of mitochondrial DNA (mtDNA) in cancer cells and the potential use of mtDNA modifications as novel targets for breast cancer treatment.

SEMINARS IN CANCER BIOLOGY (2022)

添加到收藏夹

Article Oncology

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Francois-Clement Bidard, Virginia G. Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frederic Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K. Harnden, Hung Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, Jose A. Garcia Saenz, Emilio Bria, Marina Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortes, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia

Summary: Elacestrant, a novel oral selective estrogen receptor degrader, demonstrated significant improvement in progression-free survival in patients with pretreated estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer, including those with ESR1 mutations, with manageable adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Head and Neck Cancers, Version 1.2022 Featured Updates to the NCCN Guidelines

Jimmy J. Caudell, Maura L. Gillison, Ellie Maghami, Sharon Spencer, David G. Pfister, Douglas Adkins, Andrew C. Birkeland, David M. Brizel, Paul M. Busse, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Thomas Galloway, Jessica L. Geiger, Robert Haddad, Wesley L. Hicks, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, James W. Rocco, Cristina P. Rodriguez, Panayiotis S. Savvides, David Schwartz, Jatin P. Shah, David Sher, Maie St John, Randal S. Weber, Gregory Weinstein, Frank Worden, Justine Yang Bruce, Sue S. Yom, Weining Zhen, Jennifer L. Burns, Susan D. Darlow

Summary: The NCCN Guidelines for Head and Neck Cancers provide clinical treatment guidance for tumors in the oral cavity, pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary gland cancer, and mucosal melanoma. The treatment recommendations are based on the specific site of disease, stage, and pathological findings, and are continuously updated with new research data.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

添加到收藏夹

Review Oncology

An update on vitamin D signaling and cancer

Carsten Carlberg, Alberto Munoz

Summary: A low vitamin D status is associated with an increased risk of various cancers. The biologically active form of vitamin D, 1,25(OH)2D3, influences the epigenome and transcriptome of healthy and neoplastic cells, affecting their growth and differentiation.

SEMINARS IN CANCER BIOLOGY (2022)

添加到收藏夹

Article Oncology

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C. Piccione, Michael C. Wei, Shen Yin, Nancy L. Bartlett

Summary: This study evaluated the safety, tolerability, and efficacy of mosunetuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs). The results showed that mosunetuzumab has a manageable safety profile and induces durable complete responses in some patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Single-cell RNA sequencing technologies and applications: A brief overview

Dragomirka Jovic, Xue Liang, Hua Zeng, Lin Lin, Fengping Xu, Yonglun Luo

Summary: Single-cell RNA sequencing technology is an advanced method for studying the diversity and complexity of RNA transcripts within individual cells, and for understanding the composition and functions of different cell types in highly organized tissues/ organs/ organisms. This technology has made significant contributions to various fields, providing unique insights into health and diseases. It can be used to construct high-resolution atlases of cells in all living organisms, and has the potential to transform current protocols in disease diagnosis and treatment.

CLINICAL AND TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Oncology

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue

Aileen Fernandez, Matthew Liu, Andrew Bellizzi, Jane Brock, Oluwole Fadare, Krisztina Hanley, Malini Harigopal, Julie M. Jorns, M. Gabriela Kuba, Amy Ly, Mirna Podoll, Kimmie Rabe, Mary Ann Sanders, Kamaljeet Singh, Olivia L. Snir, T. Rinda Soong, Shi Wei, Hannah Wen, Serena Wong, Esther Yoon, Lajos Pusztai, Emily Reisenbichler, David L. Rimm

Summary: The current standard ERBB2 IHC assay may not be suitable for selecting patients with low ERBB2 positivity for treatment with T-DXd, as the accuracy of scoring for ERBB2 INC in the low range (0 and 1+) was poor in this study, raising the risk of misassigning patients for treatment with T-DXd.

JAMA ONCOLOGY (2022)

添加到收藏夹

Review Oncology

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Yan Peng, Yuanyuan Wang, Cheng Zhou, Wuxuan Mei, Changchun Zeng

Summary: Cancer is a global public health issue that hinders the improvement of life expectancy worldwide. Current therapeutic options are insufficient, necessitating targeted treatments. Understanding the association between the PI3K/AKT/mTOR pathway and tumorigenesis, as well as the development of therapies targeting this pathway, is crucial for clinical decision-making.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Patrick Y. Wen, Alexander Stein, Martin van den Bent, Jacques De Greve, Antje Wick, Filip Y. F. L. de Vos, Nikolas von Bubnoff, Myra E. van Linde, Albert Lai, Gerald W. Prager, Mario Campone, Angelica Fasolo, Jose A. Lopez-Martin, Tae Min Kim, Warren P. Mason, Ralf-Dieter Hofheinz, Jean-Yves Blay, Daniel C. Cho, Anas Gazzah, Damien Pouessel, Jeffrey Yachnin, Aislyn Boran, Paul Burgess, Palanichamy Ilankumaran, Eduard Gasal, Vivek Subbiah

Summary: The study evaluated the efficacy and safety of dabrafenib plus trametinib in patients with high-grade glioma and low-grade glioma who had BRAF(V600E) mutation. The results showed that dabrafenib plus trametinib demonstrated meaningful activity in the treatment of recurrent or refractory high-grade glioma and low-grade glioma with BRAF(V600E) mutation, and had a safety profile consistent with other indications.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Jessica J. Lin, Amir Vajdi, Natalie Vokes, Lingzhi Hong, Jianjun Zhang, Michael Y. Tolstorukov, Yvonne Y. Li, Liam F. Spurr, Andrew D. Cherniack, Gonzalo Recondo, Giuseppe Lamberti, Xinan Wang, Deepti Venkatraman, Joao Alessi, Victor R. Vaz, Hira Rizvi, Jacklynn Egger, Andrew J. Plodkowski, Sara Khosrowjerdi, Subba Digumarthy, Hyesun Park, Nuno Vaz, Mizuki Nishino, Lynette M. Sholl, David Barbie, Mehmet Altan, John Heymach, Ferdinandos Skoulidis, Justin F. Gainor, Matthew D. Hellmann, Mark M. Awad

Summary: STK11 and KEAP1 mutations have a negative impact on the efficacy of immunotherapy in lung adenocarcinoma, but this effect is only observed in KRAS-positive tumors. Tumors with concurrent KRAS/STK11 and KRAS/KEAP1 mutations exhibit distinct immune characteristics.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)

Robert L. Ferris, Yael Flamand, Gregory S. Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J. Garcia, Christine H. Chung, Maura L. Gillison, Umamaheswar Duvvuri, Bert W. O'Malley, Enver Ozer, Giovana R. Thomas, Wayne M. Koch, Neil D. Gross, R. Bryan Bell, Nabil F. Saba, Miriam Lango, Eduardo Mendez, Barbara Burtness

Summary: This study aimed to investigate the efficacy and safety of primary transoral surgery (TOS) and reduced postoperative radiation therapy (RT) in intermediate-risk patients with human papillomavirus-associated oropharynx cancer (HPV+ OPC). The results showed that TOS and reduced RT achieved favorable oncologic outcomes and functional outcomes in intermediate-risk HPV+ OPC patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

«
1
2
3
4
5
»

See full results

Related Categories

Anesthesiology (212.5K) Audiology & Speech-Language Pathology (1.7K) Clinical Neurology (1.3M) Critical Care Medicine (338.4K) Dentistry, Oral Surgery & Medicine (340.8K) Dermatology (413.6K) Emergency Medicine (142.9K) Endocrinology & Metabolism (751.7K) Gastroenterology & Hepatology (856.4K) Geriatrics & Gerontology (226.3K) Gerontology (158.2K) Health Care Sciences & Services (433.8K) Hematology (653.3K) Immunology (896.7K) Infectious Diseases (453.2K) Integrative & Complementary Medicine (99.8K) Medical Ethics (26.6K) Medical Informatics (100.5K) Medical Laboratory Technology (108K) Medicine, General & Internal (1.3M) Medicine, Legal (48.4K) Medicine, Research & Experimental (710K) Nursing (297.8K) Obstetrics & Gynecology (559.8K) Ophthalmology (452.2K) Orthopedics (359.5K) Otorhinolaryngology (166K) Pediatrics (655.3K) Peripheral Vascular Disease (595.7K) Pharmacology & Pharmacy (1.3M) Primary Health Care (59.2K) Psychiatry (755.1K) Radiology, Nuclear Medicine & Medical Imaging (799.4K) Rehabilitation (249.2K) Rheumatology (300.3K) Surgery (1.3M) Toxicology (333.1K) Transplantation (309.7K) Tropical Medicine (112.2K) Urology & Nephrology (567K) Veterinary Sciences (455.3K)

© Peeref 2019-2024. All rights reserved.